INTEGRATION OF BCR, TLR, BAFF RECEPTOR AND TACI RESPONSE GENE TO COMPLEMENT-32 EXPRESSION IS A KEY TO SLE PATHOGENESIS

1Du Samuel, Jacobs Holly M, 1Arkatakar Tarvi, 1Scarpiang Nicolo, 1,2Rawlins David J, 1,3Jackson Shaun W*, 1Seattle Children’s Research Institute, University of Washington School of Medicine, Seattle, WA, USA; 2Departments of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA; 3Inmunology, University of Washington School of Medicine, Seattle, WA, USA


**Background** The B cell survival cytokine BAFF has been linked with the pathogenesis of SLE. BAFF binds distinct B cell surface receptors, including the BAFF receptor (BAFF-R) and Transmembrane Activator and CAML Interactor (TACI). Although originally characterized as a negative regulator of B cell activation, TACI signals are critical for class-switched autoantibody production in BAFF transgenic (Tg) mice. Notably, while surface TACI expression is usually limited to mature B cells, we showed that excess BAFF promotes the expansion of TACI-expressing transitional B cells, with these cells representing an important source for class-switched autoantibodies in BAFF-Tg mice (Jacobs, et al. J Immunol, 2016). In the current study, we interrogate the signals required for transitional B cell TACI expression and BAFF-driven autoantibody production.

**Methods** We first used a new “fate-mapping” strategy to confirm that activated TACI+ B cells falling within CD21lo transitional flow cytometry gates are bone fide transitional B cells. Subsequently, we interrogated the B cell signals required for transitional B cell TACI expression and antibody production using relevant murine genetic models crossed on the BAFF-Tg background.

**Results** To confirm that immature, transitional B cells are a prominent source for class-switched autoantibodies in BAFF-Tg mice, we developed a CD21Cre:ROSA-YFPfl/fl reporter strategy. By irreversibly labeling B cells that have expressed CD21, we confirmed that transitional B cells that had not yet differentiated beyond the T2 stage spontaneously produce class-switched autoantibodies in BAFF-Tg animals. We next determined the signals required for TACI upregulation on T1 transitional B cells. Surprisingly, signals downstream of B cell (BCR) and Toll-like (TLR) receptors exerted distinct impacts on transitional B cells. Whereas loss of BCR signals in Btk−/−BAFF-Tg mice prevented transitional B cell TACI expression and resulted in loss of serum autoantibodies across immunoglobulin isotypes, lack of Myd88 or TLR7 signals exerted a limited impact on autoantibody class switch recombination without impacting transitional B cell TACI expression. Moreover, in parallel with the protective effect of TACI deletion, loss of BAFF-R activation signals protected against BAFF-driven autoimmunity. Notably, integration of all these signalling cascades (BCR, TACI, TLR7/MyD88, and BAFF-R) is required for production of pathogenic class-switched autoantibodies in BAFF-Tg mice, and for development of BAFF-driven lupus nephritis.

**Conclusions** In summary, we highlight how distinct signaling pathways integrate to promote class-switched autoantibody production by transitional B cells, findings with implications to the understanding of SLE pathogenesis and other humoral autoimmune diseases characterized by elevated serum BAFF.

RESPONSE GENE TO COMPLEMENT-32 EXPRESSION IS UPREGULATED IN LUPUS T CELLS AND PROMOTES IL-17A EXPRESSION

1,2Anamaria Talpos-Caia, 1,2Alexandru Tatormir, 1,2Vinh Nguyen, 2Comelia D Cudrici, 1Simona Rednic, 1Horea G Rus, 2Violeta Rus*, 1University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania; 2University of Maryland School of Medicine, Baltimore, USA; 3Veterans Administration Maryland Health Care System, Baltimore, USA; 4NIAMS, National Institutes of Health, Bethesda, USA

**Background** RGC (Response Gene to Complement)-32 is a cell cycle regulator widely expressed in normal tissues including brain, kidney, spleen, thymus, multiple tumors and in a variety of cell lines. RGC-32 is localized in the cytoplasm and translocates to the nucleus upon upregulation by complement activation, growth factors and cytokines. RGC-32 is induced by TGFβ in fibroblasts, astrocytes and human renal proximal tubular cells and mediates TGFβ dependent profibrotic pathways. RGC-32 is preferentially upregulated in murine Th17 cells and promotes their differentiation. Patients with Systemic Lupus Erythematosus (SLE) display increased serum levels, expanded frequency of IL-17 producing cells. Whether RGC-32 plays a role in human Th17 differentiation pathway and in Th17 abnormalities in lupus patients has not yet been investigated.

**Methods** RGC-32 expression in naïve CD4+ T cells from normal controls stimulated with cytokines alone or under Th0, Th1, Th2, Th17 and Treg conditions was determined by flow cytometry and RT-PCR. RGC-32 mRNA expression in PBMCs of lupus patients was assessed with the Autoimmune Disease Profiling cDNA Array spotted with cDNA from CD3+, CD19+ and CD14+ cells and by RT-PCR and flow cytometry. RGC-32 nuclear translocation after stimulation under Th17 conditions was assessed by Western blotting. RGC-32 overexpression and silencing was performed by nucleofection and transfection. RGC-32 expression was upregulated by TCR stimulation and TGFβ and was more robust under Th17 (3.2±0.6 fold) and Treg (2.6±0.8 fold) vs Th1 (1.3±0.4 fold) and Th2 (1.8±0.1 fold) conditions. Moreover, upon stimulation with anti-CD3/CD28 and TGFβ, RGC-32 was translocated into the nucleus. Other cytokines such as IFNα, IL-1β, TNFα did not upregulate RGC-32 mRNA either alone or in combination with TCR stimulation. Overexpression or silencing of RGC-32 in CD4+ T cells upregulated, respectively downregulated IL-17A transcript levels and protein secretion. RGC-32 mRNA and protein level were significantly increased in CD19+ B cells and CD3+ T from lupus patients compared to controls.

**Conclusions** These results suggest that RGC-32 promotes the differentiation of human Th17 cells. Furthermore, T cells from patients with SLE exhibit increased expression of RGC-32 compared to controls. These data support the idea that RGC-32 signaling may enhance disease expression in SLE by promoting abnormalities in the Th17 pathway and provide a compelling rationale for further investigating the therapeutic potential of blocking RGC-32 in SLE.